Stock ENTA ENANTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Market Closed - Nasdaq
Other stock markets
 21:00:01 02/05/2024 BST 		5-day change 1st Jan Change
13.94 USD +2.80% Intraday chart for Enanta Pharmaceuticals, Inc. +11.70% +48.14%
04-30 Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer CI
02-09 Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
Sector Update: Health Care
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
Enanta Pharmaceuticals Says Phase 1 Clinical Study of Oral L-Protein Inhibitor EDP-323 Yields 'Positive' Topline Data
Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Top Midday Decliners
Looming Inflation Report, Weak Chinese Data Drive Premarket Losses for US Equity Futures
Top Premarket Decliners
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
Sector Update: Health Care Stocks Declining Late Tuesday
Sector Update: Health Care
Enanta Pharmaceuticals Sells Part of Future Royalties of Mavyret Global Sales to OMERS for $200 Million
Enanta Pharmaceuticals Says FDA Grants Fast Track Designation for EDP-323
Insider Sell: Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTA Stock
  4. News Enanta Pharmaceuticals, Inc.
  5. Other languages